bluuebunny/crossref_metadata_2025_split huggingface dataset:
Antidepressant use among survivors of childhood, adolescent and young adult cancer: A report of the childhood, adolescent and young adult cancer survivor (CAYACS) research program
Authors: Deyell Rebecca J. , Lorenzi Maria , Ma Suli , Rassekh Shahrad R. , Collet Jean‐Paul , Spinelli John J. , McBride Mary L. 
Published: January 2013

AbstractBackgroundAlthough survivors of childhood, adolescent, and young adult (AYA) cancer are at risk for late psychological sequelae, it is unclear if they are more likely to be prescription antidepressant users than their peers.ProcedureAll 5‐year survivors of childhood or AYA cancer diagnosed before age 25 years in British Columbia from 1970 to 1995 were identified. Those with complete follow‐up in the provincial health insurance registry from 2001 to 2004 were included (n = 2,389). A birth‐cohort and gender‐matched set of population controls 10 times the size of the survivor group was randomly selected (n = 23,890). All prescriptions filled between 2001 and 2004 were identified through linkage to the provincial prescription drug administrative database. Logistic regression analyses determined the impact of cancer survivorship on the likelihood of ever filling an antidepressant prescription.ResultsAfter adjusting for sociodemographic factors, survivors of childhood and AYA cancer were more likely to have filled an antidepressant prescription compared to controls (OR 1.21, 95% CI 1.09–1.35). Cancer survivors had an increased likelihood of using all categories of antidepressants, and of using drugs from two or more antidepressant categories, compared to peers (OR 1.31, 95% CI 1.11–1.55 [≥2 antidepressant categories]). Treatment was not a significant predictor of antidepressant use. Female survivors, those in young adulthood and those more than 20 years post‐treatment had increased antidepressant use.ConclusionsSurvivors of childhood and AYA cancer are more likely to fill antidepressant prescriptions compared to peer controls. This may indirectly reflect an increased underlying prevalence of mental health conditions among survivors. Pediatr Blood Cancer 2013; 60: 816–822. © 2012 Wiley Periodicals, Inc.
Pathological fracture as the presenting feature in pediatric osteosarcoma
Authors: Lee Ryan K.L. , Chu Winnie C.W. , Leung Joyce H.Y. , Cheng Frankie W.T. , Li C.K. 
Published: January 2013

AbstractBackgroundPathological fracture is an uncommon presentation in patients with long bone osteosarcoma.ProceduresWe retrospectively reviewed the database of all patients with histologically proven osteosarcoma under the age of 18 years from 1991 to 2011 in a tertiary pediatric oncology referral center. Five patients with pathological fractures as the first presentation of osteosarcoma were identified. The treatment strategies and complications were evaluated. Ten sex‐, age‐, and site‐ matched osteosarcoma patients without pathological fracture were selected as controls. The incidence of distant metastases and outcome, including local recurrence and survival, were compared between the index (with pathological fracture) and the control (without pathological fracture) groups.ResultsIn the index group, all five patients were boys and the mean age of onset was 13.1 years (range 9.2–14.9). Three patients (60%, 3/5) received amputation and two (40%) had wide local excision of the tumor. Pathological fracture group showed higher rate of lung (60% vs. 10%, P = 0.04) and bone (60% vs. 10%, P = 0.04) metastases at presentation, and shorter overall 5‐year survival (P = 0.04) than the control group. There was no significant difference of local recurrence (20%, P = 1.00) between these two groups regardless of the type of operation.ConclusionOsteosarcoma complicated by pathological fracture as first presentation had higher incidence of lung and bone metastases at presentation and worse survival rate when compared with patients without pathological fracture. Pediatr Blood Cancer 2013; 60: 1118–1121. © 2012 Wiley Periodicals, Inc.
High frequency of streptococcal bacteraemia during childhood AML therapy irrespective of dose of cytarabine
Authors: Johannsen Katrine Helle , Handrup Mette Møller , Lausen Birgitte , Schrøder Henrik , Hasle Henrik 
Published: January 2013

AbstractBackgroundHigh‐dose cytarabine has been associated with a high frequency of viridans group streptococcal (VGS) bacteraemia. VGS bacteraemia causes considerable morbidity and mortality. The Nordic Society of Paediatric Haematology and Oncology (NOPHO)‐AML protocols use higher cumulated doses of cytarabine and more chemotherapy series (n = 6) than other protocols with the potential increased risk of severe VGS infections.ProcedureMedical records of all Danish children enrolled on the NOPHO‐AML‐2004 protocol between January 2004 and September 2011 (n = 45) were retrospectively reviewed and all febrile episodes were registered.ResultsFollowing 236 courses of chemotherapy, 112 positive blood cultures were registered. VGS were found in 38% of all positive blood cultures. Infectious episodes with VGS resulted in more days of fever and intravenous antibiotic therapy compared with infections caused by other microorganisms. VGS were involved in 45% of all episodes categorized as sepsis (n = 51) and in 67% of life‐threatening bloodstream infections (n = 9). Penicillin resistance was found in 40% of the VGS strains. No significant difference was observed in the proportion of VGS isolated following courses with low‐dose cytarabine versus courses with high‐dose cytarabine.ConclusionsVGS were the most commonly isolated pathogens causing the most severe infections and the majority of life‐threatening infections. A substantial proportion of the strains were resistant to penicillin. The high rate of VGS seemed independent of high‐dose cytarabine but was more likely caused by the intensive chemotherapy treatment leading to severe mucositis and neutropenia. Pediatr Blood Cancer 2013; 60: 1154–1160. © 2012 Wiley Periodicals, Inc.
Decision making in pediatric oncology: Evaluation and incorporation of patient and parent preferences
Authors: Sung Lillian , Regier Dean A. 
Published: January 2013

AbstractDecision making in pediatric cancer is particularly difficult. There may be uncertainty about prognosis, and long‐term survival estimates from trials may not be applicable to current patients. There are many motivations to conduct research into patient and provider decision making. This review discusses three approaches to understanding decision making, namely decision analysis, the threshold technique and discrete choice experiment. These techniques are applied to situations in pediatric oncology to illustrate how the results may be useful for patient care. Future work in pediatric oncology decision making should focus on methods to facilitate decision making and elicit preferences from children themselves. Pediatr Blood Cancer 2013; 60: 558–563. © 2012 Wiley Periodicals, Inc.
Long‐term follow‐up of children with high‐risk neuroblastoma: The ENSG5 trial experience
Authors: Moreno Lucas , Vaidya Sucheta J. , Pinkerton C. Ross , Lewis Ian J. , Imeson John , Machin David , Pearson Andrew D. J. ,   on behalf of the European Neuroblastoma Study Group and the Children's Cancer and Leukaemia Group (CCLG) (formerly UKCCSG)
Published: January 2013

AbstractBackgroundTherapy for high‐risk neuroblastoma is intensive and multimodal, and significant long‐term adverse effects have been described. The aim of this study was to identify the nature and severity of late complications of metastatic neuroblastoma survivors included in the ENSG5 clinical trial.ProcedureThe trial protocol included induction chemotherapy (randomized “Standard” OPEC/OJEC vs. “Rapid” COJEC), surgery of primary tumor and high‐dose melphalan with stem cell rescue. Two hundred and sixty‐two children were randomized, 69 survived >5 years, and 57 were analyzed. Data were obtained from the ENSG5 trial database and verified with questionnaires sent to participating centers.ResultsMedian follow‐up was 12.9 (6.9–16.5) years. No differences were found in late toxicities between treatment arms. Twenty‐eight children (49.1%) developed hearing loss. Nine patients (15.8%) developed glomerular filtration rate <80 ml/min/1.73 m2, but no cases of chronic renal failure were documented. Endocrine complications (28.1% of children) included mainly hypogonadism and delayed growth. Four children developed second malignancies, three of them 5 years after diagnosis: one osteosarcoma, one carcinoma of the parotid gland and one ependymoma. There were no hematological malignancies or deaths in remission.ConclusionsThis study analyzed a wide cohort of high‐risk neuroblastoma survivors from a multi‐institutional randomized trial and established the profile of long‐term toxicity within the setting of an international clinical trial. Pediatr Blood Cancer 2013; 60: 1135–1140. © 2012 Wiley Periodicals, Inc.
Safety and efficacy of high‐dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study
Authors: Skapek Stephen X. , Anderson James R. , Hill D. Ashley , Henry David , Spunt Sheri L. , Meyer William , Kao Simon , Hoffer Fredric A. , Grier Holcombe E. , Hawkins Douglas S. , Raney R. Beverly 
Published: January 2013

AbstractBackgroundDesmoid fibromatosis (desmoid tumor, DT) is a soft tissue neoplasm prone to recurrence despite complete surgical resection. Numerous small retrospective reports suggest that non‐cytotoxic chemotherapy using tamoxifen and sulindac may be effective for DT. We evaluated the safety and efficacy of tamoxifen and sulindac in a prospective phase II study within the Children's Oncology Group.ProceduresEligible patients were <19 years of age who had measurable DT that was recurrent or not amenable to surgery or radiation. The primary objective was to estimate progression‐free survival (PFS). Patients received tamoxifen and sulindac daily for 12 months or until disease progression or intolerable toxicity occurred. Response was assessed by magnetic resonance imaging.ResultsFifty‐nine eligible patients were enrolled from 2004 to 2009; 78% were 10–18 years old. Twenty‐two (38%) were previously untreated; 15 (41%) of the remaining 37 enrolling with recurrent DT had prior systemic chemotherapy and six (16%) had prior radiation. No life‐threatening toxicity was reported. Twelve (40%) of 30 females developed ovarian cysts, which were asymptomatic in 11 cases. Ten patients completed therapy without disease progression or discontinuing treatment. Responses included four partial and one complete (5/59, 8%). The estimated 2‐year PFS and survival rates were 36% (95% confidence interval: 0.23–0.48) and 96%, respectively. All three deaths were due to progressive DT.ConclusionsTamoxifen and sulindac caused few serious side effects in children with DT, although ovarian cysts were common. However, the combination showed relatively little activity as measured by response and PFS rates. Pediatr Blood Cancer 2013; 60: 1108–1112. © 2012 Wiley Periodicals, Inc.
Improvement of toughness in polypropylene nanocomposite with the addition of organoclay/silicone copolymer masterbatch
Authors: Kaneko Manuela L.Q.A. , Romero Rafaelle B. , de Paiva Raphael E.F. , Felisberti Maria I. , Gonçalves Maria C. , Yoshida Inez V.P. 
Published: January 2013

AbstractPolypropylene nanocomposites were prepared with organic‐modified montmorillonite, by blending the polymer and the organoclay (direct addition), or by blending the polymer with an organoclay/silicone copolymer masterbatch. The effect of the organoclay/silicone copolymer masterbatch on the morphology and properties of polypropylene was compared with that nanocomposite obtained with the direct organoclay addition. The results showed that the morphology of both polypropylene nanocomposites is constituted by clay tactoids together with some few individual platelets and clay aggregates. Smaller tactoids were observed for the nanocomposite prepared with the masterbatch, in which the silicone copolymer remained intercalated in the clay or adjacent to tactoids. The introduction of the organoclay in the polymer matrix resulted only in an increase in the Young's modulus (28%), while yielding stress, elongation at break and Izod impact strength remained practically unchanged. On the other hand, the incorporation of organoclay by using the masterbatch resulted in a marked improvement (111%) in the elongation at break and in Izod impact strength (85%). The improvement in the elongation at break came with the reduction of the modulus and the yielding stress, by 25 and 15%, respectively. POLYM. COMPOS., 2013. © 2013 Society of Plastics Engineers
Role of calcium stearate as a dispersion promoter for new generation carbon black‐organoclay based rubber nanocomposites for tyre application
Authors: Mohanty Tapas R , Bhandari Vivek , Chandra Arup K. , Chattopadhyay Pijush K. , Chattopadhyay Santanu 
Published: January 2013

AbstractA novel carbon black (CB) and nanoclay (NC) dual phase‐filled system in SBR matrix has been developed to be employed as a tyre tread compound with optimized performance properties. The nanocomposite has shown improved dynamic properties i.e. rolling resistance (tan δ at 60°C) and wet skid resistance (tan δ at 0°C), for relatively lower loading of NC (3 phr). However, the mechanical properties and wear resistance combined with above mentioned dynamic properties have been further improved by direct substitution of stearic acid with calcium stearate. This has been argued to be due to enhanced filler‐rubber interaction by the strong ionic interactions between the calcium ion (Ca++) and layered silicates (NC) having anionic surface. Transmission electron microscopy and low angle X‐ray diffraction studies have revealed the role of calcium stearate as a dispersion promoter for organoclay. Fourier transform infra‐red spectroscopy study has shown a shift in the SiOSi bond towards lower wave number indicating better polymer‐clay interaction. A detailed investigation on the dynamic rheological behavior of SBR‐CB‐NC nanocomposites has been carried out using rubber process analyzer to invoke an insight into the processing behavior of these composites. POLYM. COMPOS., 2013. © 2013 Society of Plastics Engineers
Adsorption of cadmium (II) and copper (II) ions from aqueous solution using chitosan composite
Authors: Ramya R. , Sudha P.N. 
Published: January 2013

AbstractThe binary chitosan/silk fibroin composite synthesized by reinforcement of silk fibroin fiber into the homogenous solution of chitosan in formic acid was used to investigate the adsorption of two metals of Cu(II) and Cd(II) ions in an aqueous solution. The binary composite was characterized by Fourier transform infrared and scanning electron microscopy. The optimum conditions for adsorption by using a batch method were evaluated by changing various parameters such as contact time, adsorbent dose, and pH of the solution. The experimental isotherm data were analyzed using the Freundlich and Langmuir equations, indicated to be well fitted to the Langmuir isotherm equation under the concentration range studied, by comparing the correlation co‐efficient. Adsorption kinetics data were tested using pseudo‐first‐order and pseudo‐second‐order models. Kinetics studies showed that the adsorption followed a pseudo‐second‐order reaction. Due to good performance and low cost, this binary chitosan/silk fibroin composite can be used as an adsorbent for removal of Cu(II) and Cd(II) from aqueous solutions. POLYM. COMPOS., 2013. © 2013 Society of Plastics Engineers
Evaluation of FDA safety‐related drug label changes in 2010
Authors: Lester Jean , Neyarapally George A. , Lipowski Earlene , Graham Cheryl Fossum , Hall Marni , Dal Pan Gerald 
Published: January 2013

ABSTRACTPurposeThis study characterizes drug safety‐related label changes by evidence source contribution, time from drug approval to label change, initiator (FDA or sponsor), and drug class.MethodsA retrospective review of the FDA's internal files was used to obtain regulatory documentation on drugs undergoing a 2010 label change. Contribution of evidence sources were identified and label change initiator and drug class were determined for each drug.ResultsA total of 371 drugs were analyzed. Spontaneous reports contributed to 52% and 55% of label changes when analyzed by unique safety issue and drug, respectively. The median time from approval to 2010 safety‐related label change was 11 years. The sponsor was more likely than the FDA to initiate a label change (58% and 42%). Label changes were most common among nervous system drugs (23%), antiinfectives for systemic use (17%), and cardiovascular system drugs (14%).ConclusionsDrug label changes involve contributions from multiple evidence sources. The findings from this comprehensive review are consistent with previous findings and demonstrate (i) the continued importance of the spontaneous reporting system and complementary evidence sources and (ii) safety‐related label changes take place years after postmarket approval, emphasizing the importance of continued drug safety surveillance throughout a product's lifecycle. Copyright © 2013 John Wiley & Sons, Ltd.
Titanium(IV) nonmetallocene complex catalyzed aqueous homopolymerization and copolymerization of styrene and methyl methacrylate: An Environmentally friendly approach to ultrahigh molecular weight polymer nanoparticles
Authors: De Sudip K. , Bhattacharjee Manish 
Published: January 2013

AbstractA new titanium(IV) complex bearing [ONO] type ligand has been synthesized, characterized, and employed as catalyst in homopolymerization and copolymerization of styrene and methyl methacrylate. In the presence of sodium tetraphenyl borate and sodium n‐dodecyl sulfate (SDS), it exhibits moderate to high activity and afford ultrahigh molecular weight polymers. © 2013 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem, 2013
MicroRNAs and lung development
Authors: Khoshgoo Naghmeh , Kholdebarin Ramin , Iwasiow Barbara Maria , Keijzer Richard 
Published: January 2013

AbstractMicroRNAs (miRNAs) constitute a large group of small (∼22 nucleotides), non‐coding RNA sequences that are highly conserved among animals, plants and microorganisms, suggesting that microRNAs represent a highly conserved and important regulatory mechanism. They have been demonstrated to play an important role in gene regulation. Recently, miRNAs have become a major focus of interest for research in organ development. Research focusing on the potential role of microRNAs during lung development is slowly starting to emerge. A number of miRNAs have been demonstrated to play important roles during early and late lung development. Several studies have begun to profile miRNA expression at various stages of lung development and this article provides an overview of the various miRNAs that have been implicated in lung organogenesis. Pediatr Pulmonol. 2013; 48:317–323. © 2012 Wiley Periodicals, Inc.
Endobronchial nocardiosis in an 11‐year‐old child
Authors: Cakir Erkan , Buyukpinarbasili Nur , Ziyade Sedat , Selcuk‐Duru Hatice N. , Bilgin Mehmet , Topuz Ufuk 
Published: January 2013

AbstractPulmonary nocardiosis is a rare infection and overwhelmingly limited to immunocompromised individuals. Endobronchial nocardiosis is even more rare. Nocardiosis is rarely seen in immunocompetent hosts mostly as cutaneous infection. Here we report an immunocompetent child with endobronchial nocardiosis presenting as nonresolving pneumonia and lung abscess. To our knowledge, this is the first case reported in the literature of endobronchial nocardiosis in a child. Pediatr Pulmonol. 2013; 48:1144–1147. © 2012 Wiley Periodicals, Inc.
The lung is involved in juvenile dermatomyositis
Authors: Pouessel Guillaume , Deschildre Antoine , Le Bourgeois Muriel , Cuisset Jean‐Marie , Catteau Benoit , Karila Chantal , Nève Véronique , Thumerelle Caroline , Quartier Pierre , Tillie‐Leblond Isabelle 
Published: January 2013

AbstractBackgroundJuvenile dermatomyositis (JDM) is the main cause of chronic idiopathic inflammatory myopathy of autoimmune origin in children. The aim of this multicenter prospective study was to describe respiratory status and treatment of children followed for JDM.Methods and patientsClinical manifestations, pulmonary function tests (PFT), chest high‐resolution computed tomography (HRCT) scan results, and treatments and their adverse effects were analyzed in children followed for JDM.ResultsTwenty‐one patients (median age: 9.9 years; range: 20 months–18 years) were included. The median of disease duration at the time of the analysis was 3 years (range: 6 months–9 years 4 months). Overall 16 (76%) of 21 children presented with a respiratory involvement related to JDM including interstitial lung disease (n = 3) and/or respiratory muscle involvement (n = 7). Seven patients presented with other nonspecific manifestations. Three children had aspiration pneumonia. A chest HRCT was performed in 15 children, and abnormalities were observed in 12. PFT were performed in 20 of 21 patients. Seven showed functional abnormalities: restrictive ventilatory defect (n = 3) or obstructive ventilatory defect (n = 4). Six patients had abnormal respiratory muscle tests, including three with a restrictive ventilatory defect and one with an obstructive ventilatory defect. One other child with an acute aspiration pneumonia had a clearly muscle respiratory involvement but was too young to perform respiratory muscle tests and confirm this diagnosis. Treatment comprised systemic corticosteroid for all patients and adjuvant immunosuppressive therapy for 11. Adverse effects linked to treatment were reported in eight patients.ConclusionThe frequency of lung involvement in children with JDM justifies systematic respiratory assessment with PFT including measures of respiratory muscle strength. We suggest that a chest HRCT scan is indicated in cases of respiratory symptoms and/or PFT abnormalities. Longitudinal studies are needed to assess pediatric characteristics, long‐term outcomes, and responses to treatment taking into account the risk–benefit ratio. Pediatr Pulmonol. 2013; 48:1016–1025. © 2012 Wiley Periodicals, Inc.